Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | HTR1A | P08908 | 5/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | PRCP | P42785 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5244909 | 0.88 | DRD2 (0.50) | DRD2HTR1AKDM4ESMN1; SMN2CA1 | |
| SCHEMBL5249004 | 0.82 | PRCP (0.47) | DRD2HTR1AKDM4ESMN1; SMN2PRCP | |
| SCHEMBL5298787 | 0.75 | KDM4E (0.59) | DRD2HTR1AKDM4ESMN1; SMN2CA1 | |
| SCHEMBL5244522 | 0.75 | PRCP (0.77) | DRD2PRCP | |
| SCHEMBL29783566 | 0.75 | PRCP (0.77) | DRD2PRCP | |
| SCHEMBL28742357 | 0.74 | CA1 (0.69) | DRD2TRPV1KDM4ESMN1; SMN2CA1 | |
| SCHEMBL5246787 | 0.71 | KDM4E (0.57) | DRD2HTR1AKDM4ESMN1; SMN2PRCP | |
| SCHEMBL5283260 | 0.71 | PRCP (0.49) | DRD2HTR1AKDM4ESMN1; SMN2PRCP | |
| SCHEMBL6256492 | 0.69 | PRCP (0.44) | DRD2HTR1APRCPCYP2D6 | |
| SCHEMBL12311999 | 0.69 | DRD2 (0.61) | DRD2PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1827435-A2 | 4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN | AMR Technology, Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006057950-A2 | 4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2006-06-01 | — | — | WO | claimed |
| US-20060111396-A1 | 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | AMR TECHNOLOGY, INC. (US) | 2006-05-25 | — | — | US | claimed |
| US-20060111393-A1 | 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | ALBANY MOLECULAR RESEARCH, INC. | 2006-05-25 | — | — | US | claimed |
| US-20040248933-A1 | Use of 4-phenyl-substituted tetrahydroisoquinolines in the treatment of pain, migraine headaches and urinary incontinence | PHARMACIA & UPJOHN COMPANY | 2004-12-09 | — | — | US | claimed |
| EP-1827435-A2 | 4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN | AMR Technology, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-7163949-B1 | 4-phenyl substituted tetrahydroisoquinolines and use thereof | AMR TECHNOLOGY, INC. (US) | 2007-01-16 | — | — | US | disclosed |
| WO-2006057950-A2 | 4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| US-20060111396-A1 | 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | AMR TECHNOLOGY, INC. (US) | 2006-05-25 | — | — | US | disclosed |
| US-20060111393-A1 | 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | ALBANY MOLECULAR RESEARCH, INC. | 2006-05-25 | — | — | US | disclosed |
| US-20040248933-A1 | Use of 4-phenyl-substituted tetrahydroisoquinolines in the treatment of pain, migraine headaches and urinary incontinence | PHARMACIA & UPJOHN COMPANY | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248933-A1 | Use of 4-phenyl-substituted tetrahydroisoquinolines in the treatment of pain, migraine headaches and urinary incontinence | SDHA, INA, PAH | DRD2 1305/4885HTR1A 273/4885TRPV1 150/4885 |
| US-20060111396-A1 | 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | SLC6A2, SLC18A2, SLC6A4 | DRD2 11/4885HTR1A 17/4885TRPV1 1198/4885 |
| US-20060111393-A1 | 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin | SLC6A2, SLC18A2, SLC6A4 | DRD2 11/4885HTR1A 17/4885TRPV1 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.